Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples

NCUIR > Engineering College > Institute of Materials Science and Engineering > journal & Dissertation > Item 987654321/103453

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/103453

Title:	Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples
Authors:	劉炯權;Janyasupab, Metini;Lee, Ying-Hui;Zhang, Yuan;Liu, Chen W;Cai, Jieyi;Popa, Adriana;Samia, Anna C;Wang, Kuan W;Xu, Jiaqiang;Hu, Chi-Chang;Wendt, Michael K;Schiemann, Barbara J;Thompson, Cheryl L;Yen, Yun;Schiemann, William P;Liu, Chung C
Contributors:	工學院材料科學與工程研究所
Date:	2015-08-01
Issue Date:	2026-04-23 11:30:47 (UTC+8)
Publisher:	Bentham Science Publishers B.V.;United Arab Emirates: Bentham Science Publishers Ltd
Abstract:	摘要： Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in patent number WO2014052962 (2014). 其他題名： RPBM 出版者： United Arab Emirates: Bentham Science Publishers Ltd 出版日期： 2015-01-01 出處： Recent patents on biomarkers, 2015-01, Vol.5 (2), p.93-100 識別號： ISSN: 2210-3090 識別號： ISSN: 2210-3104 識別號： EISSN: 2210-3104 識別號： DOI: 10.2174/2210309005666150804195033 識別號： PMID: 28670509
Appears in Collections:	[Institute of Materials Science and Engineering] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	26	View/Open

社群 sharing

Loading...